{"success":true,"data":{"pressRelease":{"id":"17168","rtpr_id":"nPn2jKvn5a","ticker":"ATRA","exchange":"NASDAQ","all_tickers":["ATRA"],"title":"ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026","author":"PR Newswire","published_at":"2026-05-01T13:52:00.021Z","article_body":"ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026\n\nPR Newswire\n\nNEW YORK, May 1, 2026\n\nFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1275093299&u=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&a=James+(Josh)+Wilson)\nEncourages Investors Who Suffered Losses In Atara To Contact Him Directly To\nDiscuss Their Options\n\nIf you purchased or acquired securities in Atara\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1401824985&u=https%3A%2F%2Fwww.faruqilaw.com%2FATRA&a=Atara)\nbetween May 20, 2024 and January 9, 2026 and would like to discuss your legal\nrights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292\nor 212-983-9330 (Ext. 1310).\n\n[You may also click here for additional information]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1575296441&u=https%3A%2F%2Fwww.faruqilaw.com%2FATRA&a=%5BYou+may+also+click+here+for+additional+information%5D)\n\nNEW YORK, May 1, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=2734713249&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=Faruqi+%26+Faruqi%2C+LLP)\n, a leading national securities law firm, is investigating potential claims\nagainst Atara Biotherapeutics, Inc. (\"Atara\" or the \"Company\") (NASDAQ: ATRA)\nand reminds investors of the May 22, 2026 deadline to seek the role of lead\nplaintiff in a federal securities class action that has been filed against the\nCompany.\n\n(https://mma.prnewswire.com/media/2457438/Faruqi_Logo.html)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in\nNew York, Pennsylvania, California and Georgia. The firm has recovered\nhundreds of millions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=3179988905&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (1) certain manufacturing issues, as well as\ndeficiencies inherent in the ALLELE study, made it unlikely that the FDA would\napprove the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory\nprospects were overstated; (3) the aforementioned manufacturing issues also\nsubjected Atara to a heightened risk of regulatory scrutiny, as well as\njeopardized its ongoing clinical trials; (4) all the foregoing was likely to\nhave a significant negative impact on Atara's business and financial\ncondition; and (5) as a result, Defendants' public statements were materially\nfalse and/or misleading at all relevant times.\n\nOn January 12, 2026, Atara issued a press release \"announc[ing] that the U.S.\nFood and Drug Administration (FDA) has issued a Complete Response Letter (CRL)\nfor the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as\nmonotherapy treatment for adult and pediatric patients two years of age and\nolder with Epstein-Barr virus positive post-transplant lymphoproliferative\ndisease (EBV+ PTLD), who have received at least one prior therapy including an\nanti-CD20 containing regimen.\" Atara said that \"[t]he CRL indicates that the\nFDA is unable to approve the EBVALLO™ BLA in its present form\" because,\naccording to the CRL, \"the single arm ALLELE trial, which was previously\nconfirmed by the FDA as adequate to support the BLA filing, is no longer\nconsidered to be adequate to provide evidence of effectiveness for accelerated\napproval. Furthermore, the FDA stated that the trial's interpretability is\nconfounded due to trial study design, conduct, and analysis.\"\n\nOn this news, Atara's stock price fell $7.79 per share, or 56.99%, to close at\n$5.88 per share on January 12, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nAtara's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Atara class action, go to www.faruqilaw.com/ATRA\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=2837140263&u=https%3A%2F%2Fwww.faruqilaw.com%2FATRA&a=www.faruqilaw.com%2FATRA)\nor call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=3060127666&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffaruqi-%26-faruqi-llp%2F&a=LinkedIn)\n, on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=3458957954&u=https%3A%2F%2Fx.com%2Ffaruqilaw&a=X)\n, or on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=2080456415&u=https%3A%2F%2Fwww.facebook.com%2FFaruqiLaw%2F&a=Facebook)\n.\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1985958714&u=http%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n). Prior results do not guarantee or predict a similar outcome with respect to\nany future matter. We welcome the opportunity to discuss your particular case.\nAll communications will be treated in a confidential manner.\n\n(https://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/atra-shareholder-reminder-faruqi--faruqi-llp-reminds-atara-biotherapeutics-atra-investors-of-securities-class-action-deadline-on-may-22-2026-302759771.html\n(https://www.prnewswire.com/news-releases/atra-shareholder-reminder-faruqi--faruqi-llp-reminds-atara-biotherapeutics-atra-investors-of-securities-class-action-deadline-on-may-22-2026-302759771.html)\n\nSOURCE Faruqi & Faruqi, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2457438/Faruqi_Logo.jpg\nhttps://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2jKvn5a","title":"ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026","author":"PR Newswire","ticker":"ATRA","created":"2026-05-01T13:52:00.021Z","tickers":["ATRA"],"exchange":"NASDAQ","article_body":"ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026\n\nPR Newswire\n\nNEW YORK, May 1, 2026\n\nFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1275093299&u=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&a=James+(Josh)+Wilson)\nEncourages Investors Who Suffered Losses In Atara To Contact Him Directly To\nDiscuss Their Options\n\nIf you purchased or acquired securities in Atara\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1401824985&u=https%3A%2F%2Fwww.faruqilaw.com%2FATRA&a=Atara)\nbetween May 20, 2024 and January 9, 2026 and would like to discuss your legal\nrights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292\nor 212-983-9330 (Ext. 1310).\n\n[You may also click here for additional information]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1575296441&u=https%3A%2F%2Fwww.faruqilaw.com%2FATRA&a=%5BYou+may+also+click+here+for+additional+information%5D)\n\nNEW YORK, May 1, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=2734713249&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=Faruqi+%26+Faruqi%2C+LLP)\n, a leading national securities law firm, is investigating potential claims\nagainst Atara Biotherapeutics, Inc. (\"Atara\" or the \"Company\") (NASDAQ: ATRA)\nand reminds investors of the May 22, 2026 deadline to seek the role of lead\nplaintiff in a federal securities class action that has been filed against the\nCompany.\n\n(https://mma.prnewswire.com/media/2457438/Faruqi_Logo.html)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in\nNew York, Pennsylvania, California and Georgia. The firm has recovered\nhundreds of millions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=3179988905&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (1) certain manufacturing issues, as well as\ndeficiencies inherent in the ALLELE study, made it unlikely that the FDA would\napprove the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory\nprospects were overstated; (3) the aforementioned manufacturing issues also\nsubjected Atara to a heightened risk of regulatory scrutiny, as well as\njeopardized its ongoing clinical trials; (4) all the foregoing was likely to\nhave a significant negative impact on Atara's business and financial\ncondition; and (5) as a result, Defendants' public statements were materially\nfalse and/or misleading at all relevant times.\n\nOn January 12, 2026, Atara issued a press release \"announc[ing] that the U.S.\nFood and Drug Administration (FDA) has issued a Complete Response Letter (CRL)\nfor the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as\nmonotherapy treatment for adult and pediatric patients two years of age and\nolder with Epstein-Barr virus positive post-transplant lymphoproliferative\ndisease (EBV+ PTLD), who have received at least one prior therapy including an\nanti-CD20 containing regimen.\" Atara said that \"[t]he CRL indicates that the\nFDA is unable to approve the EBVALLO™ BLA in its present form\" because,\naccording to the CRL, \"the single arm ALLELE trial, which was previously\nconfirmed by the FDA as adequate to support the BLA filing, is no longer\nconsidered to be adequate to provide evidence of effectiveness for accelerated\napproval. Furthermore, the FDA stated that the trial's interpretability is\nconfounded due to trial study design, conduct, and analysis.\"\n\nOn this news, Atara's stock price fell $7.79 per share, or 56.99%, to close at\n$5.88 per share on January 12, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nAtara's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Atara class action, go to www.faruqilaw.com/ATRA\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=2837140263&u=https%3A%2F%2Fwww.faruqilaw.com%2FATRA&a=www.faruqilaw.com%2FATRA)\nor call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=3060127666&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffaruqi-%26-faruqi-llp%2F&a=LinkedIn)\n, on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=3458957954&u=https%3A%2F%2Fx.com%2Ffaruqilaw&a=X)\n, or on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=2080456415&u=https%3A%2F%2Fwww.facebook.com%2FFaruqiLaw%2F&a=Facebook)\n.\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4677925-1&h=1985958714&u=http%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n). Prior results do not guarantee or predict a similar outcome with respect to\nany future matter. We welcome the opportunity to discuss your particular case.\nAll communications will be treated in a confidential manner.\n\n(https://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/atra-shareholder-reminder-faruqi--faruqi-llp-reminds-atara-biotherapeutics-atra-investors-of-securities-class-action-deadline-on-may-22-2026-302759771.html\n(https://www.prnewswire.com/news-releases/atra-shareholder-reminder-faruqi--faruqi-llp-reminds-atara-biotherapeutics-atra-investors-of-securities-class-action-deadline-on-may-22-2026-302759771.html)\n\nSOURCE Faruqi & Faruqi, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2457438/Faruqi_Logo.jpg\nhttps://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T13:52:00.064236783Z","server_sent_at_ms":1777643520064},"received_at":"2026-05-01T13:52:03.877Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}